Quick Answer
Ultragenyx Pharmaceutical Inc. reported Total Assets of $1.53 billion for the year ending 2025.
- Ultragenyx Pharmaceutical Inc. showed an increase of +1.9% in Total Assets from 2024 to 2025.
- This data is from Ultragenyx Pharmaceutical Inc.'s annual report (Form 10-K), filed with the SEC on February 18, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: $172.71 million | Q2 2014: $162.59 million | Q3 2014: $210.93 million | Q1 2015: $355.84 million | Q2 2015: $343.00 million | Q3 2015: $602.13 million | Q1 2016: $524.18 million | Q2 2016: $481.95 million | Q3 2016: $515.17 million | Q1 2017: $545.82 million | Q2 2017: $497.54 million | Q3 2017: $435.05 million | Q1 2018: $817.35 million | Q2 2018: $806.02 million | Q3 2018: $765.15 million | Q1 2019: $1.01 billion | Q2 2019: $958.93 million | Q3 2019: $879.94 million | Q1 2020: $1.23 billion | Q2 2020: $1.31 billion | Q3 2020: $1.27 billion | Q1 2021: $1.60 billion | Q2 2021: $1.51 billion | Q3 2021: $1.48 billion | Q1 2022: $1.38 billion | Q2 2022: $1.32 billion | Q3 2022: $1.62 billion | Q1 2023: $1.38 billion | Q2 2023: $1.31 billion | Q3 2023: $1.24 billion | Q1 2024: $1.31 billion | Q2 2024: $1.62 billion | Q3 2024: $1.54 billion | Q1 2025: $1.31 billion | Q2 2025: $1.31 billion | Q3 2025: $1.19 billion.
- Over the full 13 years of available data (2013 to 2025), Ultragenyx Pharmaceutical Inc.'s Total Assets has grown by 2,468.4%.
- Historical annual values: Fiscal year 2025: $1.53 billion | Fiscal year 2024: $1.50 billion | Fiscal year 2023: $1.49 billion | Fiscal year 2022: $1.55 billion | Fiscal year 2021: $1.52 billion | Fiscal year 2020: $1.76 billion | Fiscal year 2019: $1.14 billion | Fiscal year 2018: $719.56 million | Fiscal year 2017: $490.75 million | Fiscal year 2016: $540.63 million | Fiscal year 2015: $559.57 million | Fiscal year 2014: $197.97 million | Fiscal year 2013: $59.65 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: